問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of Hematology & Oncology

Digestive System Department

Division of General Internal Medicine

Taipei Veterans General Hospital (在職)

Division of Hematology & Oncology

National Health Research Institutes (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

National Taiwan University Hospital

Division of Hematology & Oncology

更新時間：2024-06-04

陳立宗Chen, Li-Tzong
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

  • yuchichang303@nhri.edu.tw

Recruiting Trial

61Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳立宗

List

132Cases

2024-12-01 - 2031-05-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2011-12-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2011-07-01 - 2013-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Study ended11Sites

2022-03-01 - 2022-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-10-17 - 2023-10-26

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2006-01-01 - 2007-12-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Study ended3Sites

2021-10-20 - 2023-11-02

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2017-06-28 - 2020-12-31

Phase I

A Phase I safety and tolerability study of T-1101 (Tosylate) as a powder for constitution (OPC) in patients with advanced refractory solid tumors

  • Condition/Disease

    Advanced Refractory Solid Tumors

  • Test Drug

    T-1101 (Tosylate)

Participate Sites
5Sites

Suspended4Sites

白禮源
China Medical University Hospital-Taipei

未分科

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2018-01-17 - 2020-04-30

Phase I

An Extension Study of T-1101 (Tosylate) Administered Orally to Patients With Advanced Refractory Solid Tumors

  • Condition/Disease

    Advanced Refractory Solid Tumors

  • Test Drug

    T-1101 (Tosylate)

Participate Sites
5Sites

Suspended4Sites

趙祖怡
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

2012-07-01 - 2015-07-31

Phase I

A Multicenter, Phase 1/1b Open-Label, Dose-Escalation Study of ABT-700, a Monoclonal Antibody, in Subjects with Advanced Solid Tumor

  • Condition/Disease

    Advance solid tumor/non-small cell lung cancer/astric/gastroesophageal junction adenocarcinoma

  • Test Drug

    ABT-700

Participate Sites
3Sites

Terminated3Sites

夏德椿
China Medical University Hospital

Division of Thoracic Medicine

1 6 7 8 9 10 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB